Non-coding rnas (ncrna) for the diagnosis of cognitive disorders
AssigneeAmoneta Diagnostics
InventorsHueseyin FIRAT, Saliha MOUSSAOUI, Eric SCHORDAN
Life of this patent
Estimating the term…
Abstract
The present invention describes a method for the diagnosis of a cognitive disorder including but not limited to Alzheimer disease in a subject at risk of having or developing a cognitive disorder.
Claims14
A method for diagnosing or treating a cognitive disorder including but not limited to Alzheimer disease in a subject at risk of having or developing a cognitive disorder, comprising:
- (a) isolating a biological sample from the subject;
- (b) detecting a level of expression in a ncRNA (miRNA and/or lncRNA) signature, the ncRNA signature comprising or consisting of at least one ncRNA (miRNA and/or lncRNA) selected from 406 miRNAs listed in Table 1 and 1008 lncRNAs listed in Table 5 in the biological sample from said subject;
- (c) comparing the level of expression in the sample to a level of expression in a reference, wherein an increased or decreased level of expression in the sample compared to the level in the reference identifies the subject having a cognitive disorder or being at risk of developing a cognitive disorder.
A kit for diagnosing and/or monitoring a cognitive disorder including but not limited to AD, comprising at least one reagent for the determination of a ncRNA expression profile comprising or consisting of at least one ncRNA (miRNA and/or lncRNA) selected from 406 miRNAs listed in Table 1 and 1008 lncRNAs listed in Table 5.
A targeted sequencing panel for next generation sequencing, comprising nucleic acids specific for at least one ncRNA (miRNA and/or lncRNA) selected from 406 miRNAs listed in Table 1 and 1008 lncRNAs listed in Table 5.
Dependencies are inferred from the claim text.